保守手术后预防子宫内膜异位症复发的药物治疗:成本-效果分析
本研究从医疗保健视角构建Markov模型,评估GnRH-a与口服避孕药等策略预防子宫内膜异位症保守术后复发的成本-效果。结果显示,与无治疗相比,6个月GnRH-a治疗的增量成本-效果比在深部子宫内膜异位症为每QALY 6185美元,在腹膜型为每QALY 6425美元。概率敏感性分析表明,在每QALY 7400美元阈值下,6个月GnRH-a治疗在多数情况下具有成本-效果。
要点
- 与无治疗相比,6个月GnRH-a治疗的ICER在深部子宫内膜异位症为6185美元/QALY,腹膜型为6425美元/QALY。
- 在7400美元/QALY阈值下,概率敏感性分析显示6个月GnRH-a治疗在多数情况下具有成本-效果。
- 单因素敏感性分析显示缓解率和效用值等为重要影响因素。
核心结论
- 6个月GnRH-a治疗可能是预防子宫内膜异位症复发的高度成本-效果选择。
研究设计与样本
- 基于已发表临床数据构建Markov模型,从医疗保健视角进行成本-效果分析,评估至绝经 onset 的健康与经济结局。
- 研究对象为接受保守性腹腔镜或开腹手术治疗子宫内膜异位症的患者,数据来自中国卫生资源有限环境。
- 直接医疗成本与资源利用基于中国医疗保健环境,并进行了敏感性分析。
主要发现
- 与无治疗相比,6个月GnRH-a治疗的增量成本-效果比在深部子宫内膜异位症为每QALY 6185美元,在腹膜型子宫内膜异位症为每QALY 6425美元。
- 单因素敏感性分析显示缓解率和效用值等为重要影响因素。
- 概率敏感性分析表明,在每QALY 7400美元阈值下,6个月GnRH-a治疗在多数情况下具有成本-效果,无论子宫内膜异位症类型如何。
关键数值与推荐
- 增量成本-效果比:深部子宫内膜异位症为每QALY 6185美元,腹膜型为每QALY 6425美元(6个月GnRH-a治疗 vs 无治疗)。
- 成本-效果阈值:每QALY 7400美元。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the cost-effectiveness of different strategies, including gonadotropin-releasing hormone agonist (GnRH-a) and oral contraceptive therapy, for the prevention of endometriosis recurrence after conservative surgery. DESIGN: Cost-effectiveness analysis from a health care perspective. SETTING: A health-resource-limited setting in China. POPULATION: Patients who underwent conservative laparoscopic or laparotomic surgery for endometriosis. METHODS: A Markov model was developed for the endometriosis disease course. Clinical data were obtained from published studies. Direct medical costs and resource utilization in the Chinese health care setting were taken into account. The health and economic outcomes were evaluated over a period from treatment initiation to menopause onset. Sensitivity analyses were carried out to test the impact of various parameters and assumptions on the model output. MAIN OUTCOME MEASURES: Quality-adjusted life years (QALYs) gained and costs from a health care perspective. RESULTS: The incremental cost-effectiveness ratio of 6-month GnRH-a therapy compared with no therapy ranged from $6,185 per QALY in deep endometriosis to $6,425 with peritoneal endometriosis. A one-way sensitivity analysis showed considerable influential factors, such as remission rates and utility values. Probabilistic sensitivity analysis indicated that 6-month GnRH-a therapy is cost-effective in most cases at a threshold of $7,400/QALY, regardless of the type of endometriosis. CONCLUSION: Six months of therapy with GnRH-a can be a highly cost-effective option for the prevention of endometriosis recurrence. TWEETABLE ABSTRACT: Gonadotropin-releasing hormone agonist is cost effective for the prevention of endometriosis recurrence.
引用
- Wu B, Yang Z, Tobe RG, et al. Medical therapy for preventing recurrent endometriosis after conservative surgery: a cost-effectiveness analysis. BJOG. 2017. PMID: 28613432. doi:10.1111/1471-0528.14786
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。